Madrigal Pharmaceuticals (NASDAQ:MDGL) versus Journey Medical (NASDAQ:DERM) Head to Head Contrast

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Journey Medical (NASDAQ:DERM) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, profitability, valuation and earnings.

Risk and Volatility

Madrigal Pharmaceuticals has a beta of -1.04, suggesting that its stock price is 204% less volatile than the S&P 500. Comparatively, Journey Medical has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500.

Valuation & Earnings

This table compares Madrigal Pharmaceuticals and Journey Medical”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$958.40 million	12.70	-$288.28 million	($12.80)	-41.22
Journey Medical	$61.86 million	2.67	-$11.43 million	($0.37)	-16.19

Journey Medical has lower revenue, but higher earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Journey Medical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Madrigal Pharmaceuticals and Journey Medical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1	3	12	1	2.76
Journey Medical	1	1	2	0	2.25

Madrigal Pharmaceuticals currently has a consensus target price of $687.00, indicating a potential upside of 30.20%. Journey Medical has a consensus target price of $13.00, indicating a potential upside of 117.03%. Given Journey Medical’s higher possible upside, analysts plainly believe Journey Medical is more favorable than Madrigal Pharmaceuticals.

Profitability

This table compares Madrigal Pharmaceuticals and Journey Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-27.32%	-50.15%	-25.44%
Journey Medical	-14.82%	-35.57%	-10.88%

Insider and Institutional Ownership

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.3% of Journey Medical shares are owned by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are owned by insiders. Comparatively, 15.0% of Journey Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Journey Medical beats Madrigal Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.